The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy. The study population included 67 consecutive patients with non-small cell lung cancer (NSCLC) in stage II or III who were operated on at the Institute of Tuberculosis, Warsaw, Poland, between 20 April 2001 and 10 March 2003. All patients received two cycles of chemotherapy consisting of cisplatin and vinorelbine prior to the operation. The response to therapy was assessed as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), on the basis of CT scans performed before and after neoadjuvant chemotherapy. p53 and HER2/neu protein expression were evaluated by immunohistochemistry (IHC) using antibodies against p53 (clone PAb 1801, Novocastra) and against HER2/neu (Dako) in paraffin-embedded specimens of tumors. A response to therapy (CR+PR) was observed in 27 patients, while 40 patients (SD+PD) were regarded as resistant to therapy. Resistance was observed significantly more often in tumors above 3 cm in diameter. p53 expression was found in 16 tumors (23.9%) and HER2/neu in 26 tumors (38.8%). We observed a nonsignificant tendency to chemoresistance in tumors with HER-2/neu overexpression and also in tumors with p53 overexpression. If we consider HER-2/neu and p53 together, chemoresistance was observed statistically significantly more often when one or both markers were positive (p<0.05). This significance was independent of tumor size.
WallerD.A.Neoadjuvant chemotherapy in non-small cell lung cancer – the UK experience.Lung Cancer2001; 34: 31–3.
3.
TsaiC-M, ChangK.T., PerngR-PCorrelation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.J Natl Cancer Inst1993; 85: 897–901.
4.
HickmanJ.A.Apoptosis and chemotherapy resistance.Eur J Cancer1996; 32A: 921–6.
5.
BrownJ.M., WoutersB.G.Apoptosis, p53, and tumor cell sensitivity to anticancer agents.Cancer Res1999; 59: 1391–9.
6.
FerreiraC.G., TolisC., GiacconeG.p53 and chemosensitivity.Ann Oncol1999; 10: 1011–21.
7.
RomW.N., HayJ.G., LeeT.C., JiangY., Tchou-WongK-M. Molecular and genetic aspects of lung cancer.Am J Respir Crit Care Med2000; 161: 1355–67.
8.
O'ConnorP.M., JackmanJ., BaeI.Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.Cancer Res1997; 57: 4285–300.
9.
NatsumeT., KobayashiM., FujimotoS.Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma.Cancer2001; 92: 386–94.
10.
LoweS.W., BodisS., McClatcheyA.p53 status and efficacy of cancer therapy in vivo.Science1994; 266: 807–10.
11.
TsaiC.M., ChangK.T., WuL.H.Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 mutations and cell proliferation characteristics in non-small cell lung cancer cell lines.Cancer Res1996; 56: 206–9.
12.
BlandinoG., LevineA.J., OrenM.Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.Oncogene1999; 18: 477–85.
13.
HungM-C, LauY-K. Basic science of HER-2/neu: a review.Semin Oncol1999; 26(Suppl 12): 51–9.
14.
TsaiC.M., ChangK.T., ChenJ.Y., ChenY.M., ChenM.H., PerngR.P.Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.Cancer Res1996; 56: 794–801.
15.
Perez-SolerR., KempB., WuQ.P.Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.Clin Cancer Res2000; 6: 4932–8.
16.
BootonR., WardT., HeighwayJ., ThatcherN.A pharmacogenomic approach to improving outcome of chemotherapy for advanced non-small cell lung cancer (NSCLC).Int J Biol Markers2004; 19: 13 (abstract).
BurkeL., FliederD.B., GuineeD.G.Prognostic implications of molecular and immunohistochemical profiles or the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.Clin Cancer Res2005; 11: 232–41.
19.
SelvaggiG., ScagliottiG.V., TorriV.HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma.Cancer2002; 94: 2669–74.
20.
GrazianoS.L., TatumA., HerndonJEIIUse of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B Study.Lung Cancer2001; 33: 115–23.
21.
OnnA., CorreaA.M., GilcreaseM.Synchronous over-expression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.Clin Cancer Res2004; 10: 136–43.
22.
KimY-C, ParkK-O, KernJ-AThe interactive effect of Ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.Lung Cancer1998; 22: 181–90.
23.
JunkerK., StachetzkiU., RademacherD.HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.Lung Cancer2005; 48: 59–67.
FujinoM., Dosaka-AkitaH., HaradaM.Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.Cancer1995; 76: 2457–63.
26.
ReinmuthN., BrandtB., KunzeW-PPloidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer.Eur Respir J2000; 16: 991–6.
27.
MitsudomiT., HamajimaN., OgawaM., TakahashiT.Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.Clin Cancer Res2000; 6: 4055–63.
28.
GregorcV., LudoviniV., PistolaL.Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.Lung Cancer2003, 39, 41–8.
29.
TanakaF., OtakeY., YanagiharaK.Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.Br J Cancer2001; 84: 263–9.
30.
SteelsE., PaesmansM., BerghmansT.Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.Eur Respir J2001; 18: 705–19.
31.
NakamuraH., KawasakiN., TaguchiM., KabasawaK.Association of HER-2 overexpression with prognosis in non small cell lung carcinoma: a metaanalysis.Cancer2005; 103: 1865–73.
32.
MeertA.P., MartinB., PaesmansM.The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.Br J Cancer2003; 89, 959–65.
33.
KawasakiM., NakanishiY., KuwanoK.The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.Clin Cancer Res1997; 3: 1195–200.
34.
Kandioler-EckersbergerD., KappelS., MittlbockM.The p53 genotype but not immunohistochemical results is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.J Thorac Cardiovasc Surg1999; 117: 744–50.
35.
BrattstromD., BergqvistM., LambergK.Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry.Med Oncol1998; 15: 255–61.
36.
BrooksK.R., ToK., MooreJ.M.B.Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.Ann Thorac Surg2003; 76: 187–93.
37.
FisherJ.R., LahmH.Validation of molecular and immunological factors with predictive importance in lung cancer.Lung Cancer2004; 45(Suppl 2): 151–61.
38.
KingT.C., AkerleyW., FanA.C.p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.Cancer2000; 89: 769–73.
39.
SafranH., KingT., ChoyH.p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.Cancer1996; 78: 1203–10.
40.
GionM.Prognostic and predictive molecular markers: are we ready for their clinical use? The opinion of a clinical biochemist.Int J Biol Markers2003; 18: 62–4.
41.
KorobowiczE., ZdunekM.Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy.Pol J Pathol2000; 51: 71–6.
